Optimal Duration of Follow-up for Assessing Antimalarial Efficacy in Pregnancy: A Retrospective Analysis of a Cohort Followed Up Until Delivery on the Thailand-Myanmar Border.
Plasmodium falciparum
duration of follow-up
efficacy
malaria
pregnancy
Journal
Open forum infectious diseases
ISSN: 2328-8957
Titre abrégé: Open Forum Infect Dis
Pays: United States
ID NLM: 101637045
Informations de publication
Date de publication:
Jul 2019
Jul 2019
Historique:
received:
15
04
2019
accepted:
04
06
2019
entrez:
9
7
2019
pubmed:
10
7
2019
medline:
10
7
2019
Statut:
epublish
Résumé
Follow-up for 28-42 days is recommended by the World Health Organization to assess antimalarial drug efficacy for nonpregnant populations. This study aimed to determine the optimal duration for pregnant women, as no specific guidance currently exists. The distributions of time to recrudescence (treatment failure), confirmed by polymerase chain reaction genotyping for different antimalarial drugs in pregnancy, were analyzed by accelerated failure time models using secondary data on microscopically confirmed recurrent falciparum malaria collected in prospective studies on the Thailand-Myanmar border between 1994 and 2010. Of 946 paired isolates from 703 women, the median duration of follow-up for each genotyped recurrence (interquartile range) was 129 (83-174) days, with 429 polymerase chain reaction-confirmed recrudescent. Five different treatments were evaluated, and 382 In low-transmission settings, antimalarial drug efficacy assessments in pregnancy require longer follow-up than for nonpregnant populations.
Sections du résumé
BACKGROUND
BACKGROUND
Follow-up for 28-42 days is recommended by the World Health Organization to assess antimalarial drug efficacy for nonpregnant populations. This study aimed to determine the optimal duration for pregnant women, as no specific guidance currently exists.
METHODS
METHODS
The distributions of time to recrudescence (treatment failure), confirmed by polymerase chain reaction genotyping for different antimalarial drugs in pregnancy, were analyzed by accelerated failure time models using secondary data on microscopically confirmed recurrent falciparum malaria collected in prospective studies on the Thailand-Myanmar border between 1994 and 2010.
RESULTS
RESULTS
Of 946 paired isolates from 703 women, the median duration of follow-up for each genotyped recurrence (interquartile range) was 129 (83-174) days, with 429 polymerase chain reaction-confirmed recrudescent. Five different treatments were evaluated, and 382
CONCLUSIONS
CONCLUSIONS
In low-transmission settings, antimalarial drug efficacy assessments in pregnancy require longer follow-up than for nonpregnant populations.
Identifiants
pubmed: 31281861
doi: 10.1093/ofid/ofz264
pii: ofz264
pmc: PMC6602886
doi:
Types de publication
Journal Article
Langues
eng
Pagination
ofz264Subventions
Organisme : Wellcome Trust
Pays : United Kingdom
Références
Antimicrob Agents Chemother. 2000 Dec;44(12):3414-24
pubmed: 11083649
Trans R Soc Trop Med Hyg. 2000 Nov-Dec;94(6):689-93
pubmed: 11198658
Trans R Soc Trop Med Hyg. 2001 Nov-Dec;95(6):651-6
pubmed: 11816439
Stat Med. 2002 Nov 30;21(22):3493-510
pubmed: 12407686
Eur J Clin Pharmacol. 2003 Oct;59(7):545-52
pubmed: 12955371
Trans R Soc Trop Med Hyg. 2003 Sep-Oct;97(5):592-4
pubmed: 15307434
Trends Parasitol. 2004 Sep;20(9):425-32
pubmed: 15324733
Antimicrob Agents Chemother. 2004 Nov;48(11):4271-80
pubmed: 15504852
J Infect Dis. 2005 Sep 1;192(5):846-53
pubmed: 16088834
Malar J. 2006 Dec 22;5:127
pubmed: 17187673
Lancet Infect Dis. 2007 Feb;7(2):105-17
pubmed: 17251081
PLoS One. 2007 Nov 14;2(11):e1166
pubmed: 18000538
Am J Trop Med Hyg. 2008 Apr;78(4):543-5
pubmed: 18385345
PLoS Med. 2008 Nov 18;5(11):e227
pubmed: 19018658
Malar J. 2009 Jan 09;8:9
pubmed: 19134201
PLoS Med. 2008 Dec 23;5(12):e253
pubmed: 19265453
Lancet Infect Dis. 2010 Jan;10(1):51-9
pubmed: 20129149
Lancet Infect Dis. 2010 Nov;10(11):762-9
pubmed: 20932805
Antimicrob Agents Chemother. 2011 Dec;55(12):5500-6
pubmed: 21947392
Br J Clin Pharmacol. 2012 Mar;73(3):467-77
pubmed: 21950338
PLoS Med. 2013;10(3):e1001398
pubmed: 23472056
Malar J. 2015 May 28;14:221
pubmed: 26017553
Malar J. 2016 Feb 18;15:99
pubmed: 26891915
N Engl J Med. 2016 Mar 10;374(10):913-27
pubmed: 26962727
Clin Infect Dis. 2016 Sep 15;63(6):784-791
pubmed: 27313266
Malar J. 2016 Sep 21;15(1):483
pubmed: 27653788
Proc Natl Acad Sci U S A. 2017 Mar 28;114(13):3515-3520
pubmed: 28289193
Malar J. 2017 Dec 13;16(1):488
pubmed: 29237461
Lancet. 2018 Apr 21;391(10130):1608-1621
pubmed: 29631781
Lancet. 1981 May 16;1(8229):1068-70
pubmed: 6112445
J Infect Dis. 1994 Oct;170(4):971-7
pubmed: 7930743
J Infect Dis. 1997 Apr;175(4):921-6
pubmed: 9086150
Am J Trop Med Hyg. 1999 Jan;60(1):14-21
pubmed: 9988316